

ESTIMATED ANNUALIZED BURDEN HOURS—Continued

Type of form	Number of respondents	Frequency of response per respondent	Average time per response (in hours)	Total annual burden hour
Biospecimen Request .....	36	1	1	36
Data Use Annual Progress Report .....	60	1	10/60	10
Biospecimen Use Annual Progress Report .....	36	1	10/60	6
Institutional Certification Template .....	36	1	5/60	3
Total .....	200	200	.....	211

Dated: January 5, 2021.  
**Jennifer M. Guimond,**  
*Project Clearance Liaison, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health.*  
 [FR Doc. 2021-00636 Filed 1-13-21; 8:45 am]  
**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel; A Solicitation of the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals (N01), Topic 100.

*Date:* February 2, 2021.  
*Time:* 11:00 a.m. to 4:00 p.m.  
*Agenda:* To review and evaluate contract proposals.

*Place:* National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G62A, Rockville, MD 20892 (Virtual Meeting).

*Contact Person:* Lynn Rust, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601

Fishers Lane, Room 3G62A, Rockville, MD 20852, (240) 669-5069, *lrust@niaid.nih.gov*. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: January 8, 2021.  
**Tyeshia M. Roberson,**  
*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2021-00577 Filed 1-13-21; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute on Drug Abuse; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel; Exploring Epigenomic or Non-Coding RNA Regulation in the Development, Maintenance, or Treatment of Chronic Pain (R61/R33 Clinical Trial Optional).

*Date:* February 22, 2021.  
*Time:* 2:00 p.m. to 4:00 p.m.  
*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health National Institute on Drug Abuse 301 North Stonestreet Avenue Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Soyoun Cho, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research, National Institute on Drug Abuse, NIH, 301

North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 594-9460, *Soyoun.cho@nih.gov*.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS)

Dated: January 8, 2021.  
**Tyeshia M. Roberson,**  
*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2021-00575 Filed 1-13-21; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**National Institute of Nursing Research; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Nursing Research Special Emphasis Panel; Modular Budget Research Project Grant for NIH Nurse Scientist Scholars.

*Date:* February 5, 2021.  
*Time:* 10:00 a.m. to 3:00 p.m.  
*Agenda:* To review and evaluate grant applications.

*Place:* National Institute of Nursing Research, National Institutes of Health, 6701 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Ming Yan, MD, Ph.D., Scientific Review Officer, Immunology (IMM), DPPS, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, RM 4205, Bethesda, MD 20892, (301) 594-0343, [yanming@mail.nih.gov](mailto:yanming@mail.nih.gov).

*Name of Committee:* National Institute of Nursing Research Special Emphasis Panel; Fellowship and Career Development.

*Date:* February 19, 2021.

*Time:* 10:00 a.m. to 2:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute of Nursing Research, National Institutes of Health, 6701 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Ming Yan, MD, Ph.D., Scientific Review Officer, Immunology (IMM), DPPS, Center for Scientific Review, National Institute of Nursing Research, National Institutes of Health, 6701 Rockledge Drive, RM 4205 Bethesda, MD 20892, (301) 594-0343, [yanming@mail.nih.gov](mailto:yanming@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.361, Nursing Research, National Institutes of Health, HHS)

Dated: January 8, 2021.

**Tyeshia Roberson,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2021-00651 Filed 1-13-21; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Board of Scientific Counselors, National Institute of Neurological Disorders and Stroke.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* Board of Scientific Counselors, National Institute of Neurological Disorders and Stroke.

*Date:* April 11-13, 2021.

*Time:* 3:00 p.m. to 12:00 p.m.

*Agenda:* To review and evaluate personnel qualifications and performance, and competence of individual investigators.

*Place:* Porter Neuroscience Research Center, Building 35A, 35 Convent Drive, Bethesda, MD 20892 (Virtual Meeting).

*Contact Person:* Lorna W. Role, Ph.D., Scientific Director, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, 35A Convent Drive, MSC 3716, Bethesda, MD 20892, [lorna.role@nih.gov](mailto:lorna.role@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: January 8, 2021.

**Tyeshia M. Roberson,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2021-00653 Filed 1-13-21; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Prospective Grant of an Exclusive Patent License: Development and Commercialization of CD33-Specific Chimeric Antigen Receptor (CAR) Therapies for CD33-Expressing Malignancies Using Natural Killer Cells (NK Cells) Transduced With Retroviral or Lentiviral Vectors

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Senti Bio ("Senti"), located in South San Francisco, CA.

**DATES:** Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before January 29, 2021 will be considered.

**ADDRESSES:** Requests for copies of the patent applications, inquiries, and comments relating to the contemplated Exclusive Patent License should be directed to: Jim Knabb, Senior Technology Transfer Manager, NCI Technology Transfer Center at Email: [jim.knabb@nih.gov](mailto:jim.knabb@nih.gov).

**SUPPLEMENTARY INFORMATION:**

## Intellectual Property

*E-097-2018-0: Anti-CD33 Chimeric Antigen Receptors for Treatment of Human Acute Myeloid Leukemia*

1. US Provisional Patent Application 62/643,015, filed March 14, 2018 (E-097-2018-0-US-01);
2. International Patent Application PCT/US2019/022,309, filed March 14, 2019 (E-097-2018-0-PCT-02)
3. United Arab Emirates Application No: P6001291/2020, filed September 13, 2020 (E-097-2018-0-AE-03)
4. Australia Application No: 2019235926, filed September 2, 2020 (E-097-2018-0-AU-04)
5. Canada Application No: 3,093,567, filed September 9, 2020 (E-097-2018-0-CA-05)
6. China Application No: 201980018105.0, filed September 9, 2020 (E-097-2018-0-CN-06)
7. Eurasia Application No: 202092044, filed September 25, 2020 (E-097-2018-0-EA-07)
8. European Patent Application No: 19714007.2, filed October 14, 2020 (E-097-2018-0-EP-08)
9. Israel Application No: 277078, filed September 1, 2020 (E-097-2018-0-IL-09)
10. India Application No: 202047039152, filed September 10, 2020 (E-097-2018-0-IN-10)
11. South Korea Application No: 2020-7029302, filed October 13, 2020 (E-097-2018-0-KR-11)
12. Mexico Application No: MX/a/2020/009472, filed September 10, 2020 (E-097-2018-0-MX-12)
13. New Zealand Application No: 767782, filed September 13, 2020 (E-097-2018-0-NZ-13)
14. Saudi Arabia Application No: 520420134, filed September 13, 2020 (E-097-2018-0-SA-14)
15. Singapore Application No: 11202008796V, filed September 9, 2020, (E-097-2018-0-SG-15)
16. United States of America Application No: 16/980,205, filed September 11, 2020 (E-097-2018-0-US-16)
17. South Africa Application No: 2020/05571, filed September 8, 2020 (E-097-2018-0-ZA-17)

The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.

The prospective exclusive license territory may be worldwide, and the fields of use may be limited to the following:

An exclusive license to:

1. The development of a CD33-specific logic-gated CAR-based